Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2018 | 1 |
2019 | 1 |
2021 | 1 |
2022 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
Page 1
The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer.
Cell Death Dis. 2022 Jul 15;13(7):611. doi: 10.1038/s41419-022-04994-4.
Cell Death Dis. 2022.
PMID: 35840561
Free PMC article.
Inhibition of PLK1 Destabilizes EGFR and Sensitizes EGFR-Mutated Lung Cancer Cells to Small Molecule Inhibitor Osimertinib.
Eggermont C, Gutierrez GJ, De Grève J, Giron P.
Eggermont C, et al.
Cancers (Basel). 2023 May 2;15(9):2589. doi: 10.3390/cancers15092589.
Cancers (Basel). 2023.
PMID: 37174055
Free PMC article.
Item in Clipboard
Targeting USP13-mediated drug tolerance increases the efficacy of EGFR inhibition of mutant EGFR in non-small cell lung cancer.
Giron P, Eggermont C, Noeparast A, Vandenplas H, Teugels E, Forsyth R, De Wever O, Aza-Blanc P, Gutierrez GJ, De Grève J.
Giron P, et al. Among authors: eggermont c.
Int J Cancer. 2021 May 15;148(10):2579-2593. doi: 10.1002/ijc.33404. Epub 2021 Jan 25.
Int J Cancer. 2021.
PMID: 33210294
Free PMC article.
Item in Clipboard
CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition.
Noeparast A, Giron P, Noor A, Bahadur Shahi R, De Brakeleer S, Eggermont C, Vandenplas H, Boeckx B, Lambrechts D, De Grève J, Teugels E.
Noeparast A, et al. Among authors: eggermont c.
Oncogene. 2019 Aug;38(31):5933-5941. doi: 10.1038/s41388-019-0866-7. Epub 2019 Jul 8.
Oncogene. 2019.
PMID: 31285551
Free PMC article.
Item in Clipboard
Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer.
Noeparast A, Giron P, De Brakeleer S, Eggermont C, De Ridder U, Teugels E, De Grève J.
Noeparast A, et al. Among authors: eggermont c.
Oncotarget. 2018 Feb 27;9(22):16110-16123. doi: 10.18632/oncotarget.24576. eCollection 2018 Mar 23.
Oncotarget. 2018.
PMID: 29662630
Free PMC article.
Item in Clipboard
Cite
Cite